All In Biotech

NDA 216354 · Teva

Austedo Xr

Deutetrabenazine · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Feb 17, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

18

11 Phase 3, 2 recruiting

FAERS reports

2,016

1,213 serious, 159 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON’S DISEASE AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of AUSTEDO XR or AUSTEDO must balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington’s disease. AUSTEDO XR and AUSTEDO are...

What it is approved for

From the label in effect Feb 28, 2025.

AUSTEDO XR ® and AUSTEDO ® are indicated in adults for the treatment of: chorea associated with Huntington’s disease [see Clinical Studies ( 14.1 )] tardive dyskinesia [see Clinical Studies ( 14.2 )] AUSTEDO XR and AUSTEDO are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated in adults for the treatment of: Chorea associated with Huntington’s disease ( 1 ) Tardive dyskinesia ( 1 )

Mechanism: The precise mechanism by which deutetrabenazine exerts its effects in the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. The major circulating metabolites (α-dihydrotetrabenazine [HTBZ] and β-HTBZ) of deutetrabenazine, are reversible inhibitors of VMAT2, resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

8 products under this application
  • AUSTEDO XR · DEUTETRABENAZINE 12MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • AUSTEDO XR · DEUTETRABENAZINE 48MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • AUSTEDO XR · DEUTETRABENAZINE 36MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • AUSTEDO XR · DEUTETRABENAZINE 24MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • AUSTEDO XR · DEUTETRABENAZINE 6MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • AUSTEDO XR · DEUTETRABENAZINE 18MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • AUSTEDO XR · DEUTETRABENAZINE 42MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • AUSTEDO XR · DEUTETRABENAZINE 30MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Deutetrabenazine" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective320
  • depression183
  • product use issue176
  • dyskinesia156
  • somnolence146
  • fatigue136
  • death131
  • product use in unapproved indication131
  • suicidal ideation119
  • tremor118
  • fall115
  • tardive dyskinesia113

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20172
20184
20198
20204
20214
202215
202359
2024485
2025734
2026701

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Austedo XR (Deutetrabenazine)

2024 spending

$597M

Beneficiaries

11,299

81,595 claims

Per beneficiary

$52,850

$224.92 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$90,977,519
2024$597,150,053

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 31 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.